Lipocine (NASDAQ:LPCN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Lipocine to post earnings of ($0.26) per share and revenue of $2.61 million for the quarter.
Lipocine Trading Down 2.0 %
Shares of NASDAQ:LPCN opened at $3.01 on Tuesday. The company has a market cap of $16.10 million, a price-to-earnings ratio of -3.96 and a beta of 1.23. The company has a 50-day moving average price of $4.23 and a 200-day moving average price of $4.56. Lipocine has a 12 month low of $2.96 and a 12 month high of $11.79.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of Lipocine in a research note on Wednesday, February 26th. They issued a “hold” rating for the company.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
See Also
- Five stocks we like better than Lipocine
- The 3 Best Fintech Stocks to Buy Now
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- 5 Top Rated Dividend Stocks to Consider
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
